A number of the original HBAN investors in software developer Phorest have been bought out for a sum averaging 10 times their initial investment.

Phorest, which provides management software for hair and beauty salons, raised €700,000 from 12 HBAN angel investors in two funding rounds in 2011 and 2013. In June of this year, the company completed a third investment round of €20 million with US investment firm, Susquehanna Growth Equity (SGE).

Esme Loans, the digital lending platform for SMEs and scale up businesses, today announced that it has entered into a partnership with Pollen Street Capital, a London-based private equity and credit manager, further enhancing Esme’s ability to serve UK SMEs.

Is Cambridge's "Silicon Fen" becoming increasingly visible on the global stage? Beauhurst has analysed the city's tech sector. 

Calculus Capital has invested £2m in software company CloudTrade.

CloudTrade’s technology – which has been patented in Europe, the US and Australia – enables companies to automatically process electronic documents such as invoices and sales orders received by email.

The software extracts information from a human-readable, machine-generated document, such as a PDF, validates it and then converts it into a data file that is fed directly into the company’s accounting system, without human intervention.

The Financial Conduct Authority has  published the next stage of the post-implementation review of peer-to-peer lending regulation.

snap40, an AI-enabled healthcare company with the mission to protect the health of every human being, today announced it has secured US $8 million in seed financing led by ADV, with participation from MMC Ventures. Total funding to date is US $10 million, and the latest investment is the largest seed financing round for a digital healthcare company in the U.K. snap40 monitors the human body in real-time using its wearable device, with accuracy equivalent to ICU monitoring. Using this real-time data, the company’s proprietary algorithms identify those whose health is at risk and proactively bring healthcare to them. Initially, snap40 is deploying this with top healthcare providers in the U.K. and the U.S.

The curtain has long since been drawn on the 2017 Bordeaux primeurs campaign and merchants the world over are doing their damnedest to expunge all memory of it from their minds, so limp has it been.

Office workers have been warned to get along with their colleagues by avoiding the ten top reasons for workplace arguments.

Sangamo Therapeutics, Inc. and TxCell S.A. have announced that they have entered into a definitive agreement on July 20, 2018 pursuant to which Sangamo will, following the completion of the contemplated acquisition of a majority stake of TxCell, file a simplified cash tender offer for the purchase of all then outstanding ordinary shares of TxCell, at a price of EUR 2.58 per share in cash, or approximately EUR 72 million, on a debt-free and cash-free basis. Subject to satisfaction of closing conditions (including in particular those relating to regulations governing foreign investments in France), Sangamo expects to complete the transaction in the fourth quarter of 2018.

Keywords Studios, the international creative and technical services provider to the global video games industry, has announcesdthat it has acquired the business and assets of Yokozuna Data from Silicon Studios Ltd, a Japanese developer of video games and middleware solutions for game production.

Following the fast-moving Brexit developments, PIMFA – the UK’s leading wealth management and financial advice association – has raised concerns on the potential impacts of a ‘no-deal’ Brexit and how it will affect private investors and PIMFA’s member firms.

A surgical and high-precision engineering company that provides  bespoke full jaw dental implant solutions in a day to patients  has received a £4m investment from BGF. London-headquartered Evo will use the funding to expand its clinics, which feature on-site dental laboratories with the latest hi-tech medical manufacturing technology across the UK and explore international growth.

Evo’s advanced, proprietary solution provides life changing treatment for patients suffering from severe dental problems caused by advanced gum disease, congenital bone loss or accidents, and who require a full jaw reconstruction.